Use of a new ocular insert versus conventional mydriasis in cataract surgery.

BACKGROUND: To compare the efficacy and safety of a new ocular insert versus conventional mydriasis in cataract surgery. METHODS: We selected 70 patients undergoing cataract surgery. Thirty five patients (Group 1) received instillation of mydriatic drops (tropicamide 1%, phenylephrine 10%, and cyclopentolate 1%) prior to surgery, and 35 patients (Group 2) had a Mydriasert insert (Théa Pharma) (0.28 mg of tropicamide and 5.4 mg of phenylephrine hydrochloride) placed in the inferior fornix. Pupil size before and after surgery, blood pressure, and heart rate were measured. RESULTS: Before surgery, pupil diameter was 9.44 ± 1.17 mm in Group 1 and 9.05 ± 1.54 in Group 2 (P > 0.05). Twenty four hours after surgery, pupil diameter was 5.20 ± 1.54 mm in Group 1 and 3.33 ± 1.15 in Group 2 (P < 0.001). There were no statistically significant differences in blood pressure or heart rate between groups. CONCLUSIONS: The effect of the Mydriasert insert was similar to conventional mydriatic agents. Pupil size was restored to normal faster when using the Mydriasert insert compared with conventional mydriatic agents for pupil dilation.

Agudeza visual a largo plazo en pacientes con degeneración macular asociada a la edad tratados con ranibizumab y persistencia de fluido subretiniano / Long-term visual acuity in patients with age-related macular degeneration and persistence of subretinal fluid after treatment with ranibizumab

Objetivo: Analizar la agudeza visual (AV) a largo plazo en pacientes con DMAE tratados con ranibizumab con persistencia de líquido subretiniano después del tratamiento de inducción y/o en los controles sucesivos. Método: Hemos revisado las historias clínicas, tomografías de coherencia óptica (OCT) y angiografías fluoresceínicas de los 216 pacientes tratados con ranibizumab entre enero de 2008 y abril del 2010, seleccionando aquellos que han presentado fluido subretiniano de forma persistente o recurrente a lo largo del seguimiento mínimo de un año. Resultados: Hemos incluido 36 ojos de 34 pacientes; 19 ojos (52,7%) presentaban persistencia y 17 (47,2%) recurrencia de fluido subretiniano a lo largo del seguimiento (media 29,06±9,28 meses).nLa media de inyecciones fue de 7,89 ± 3,2. El espesor macular central (EMC) inicial fue de 330 ± 84μm, a los 3 meses de 265,2 ± 62microm y de 294,5 ± 37μm al final del seguimiento. La AV media inicial fue de 0,3±0,2, a los 3 meses 0,43±0,2 (p<0,05) y al final del seguimiento de 0,41±0,22 (p<0,05). La aparición de hemorragias en las recurrencias se asoció con peor visión final en comparación con los que no las presentaron (p=0,004). Al final del seguimiento18 ojos (50%) continúan en tratamiento con ranibizumab, 16 ojos (44%) se mantienen en observación y 2 pacientes han fallecido. No existen diferencias entre AV y EMC entre ambos grupos. Conclusión: La persistencia o recurrencia de fluido macular subretiniano en pacientes tratados con ranibizumab no disminuye significativamente la ganancia visual obtenida después del tratamiento de inducción, a pesar de la interrupción del mismo durante el seguimiento. La aparición de hemorragias en las recurrencias se asoció con peor AV final(AU)

Objective: To analyse the long-term visual acuity (VA) in patients with age-related macular degeneration (ARMD) treated with ranibizumab, and who had persistent subretinal fluid after the induction therapy and/or in the successive controls. Materials and methods: We reviewed the medical records, optical coherence tomography (OCT) and fluorescein angiograms of 216 patients treated with ranibizumab between January 2008 and April 2010, selecting those who had persistent subretinal fluid or recurrent fluid for at least one year of follow-up. Results: A total of 36 eyes from 34 patients were included, with 19 eyes (52.7%) having persistent, and 17 (47.2%) recurrent subretinal fluid throughout the follow- up (mean 29.06±9.28 months). The average number of injections was 7.89±3.2. The central macular thickness (CMT) at the start of follow-up was 330±84μm, at 3 months 265.2±62micrem, and 294.5±37μm at the end of the follow-up. The initial mean VA was 0.3±0.2, at 3 months 0.43±0.2 (P<.05) and at the final review, 0.41±0.22 (P<.05). Haemorrhages in recurrences were associated with a worse final VA (P=.004). At the end of follow-up, 18 eyes (50%) continued with ranibizumab treatment, 16 eyes (44%) were kept under observation, and 2 patients died. There were no differences between VA and CMT between the groups. Conclusions: The persistence or recurrence of macular subretinal fluid in patients treated with ranibizumab does not significantly reduce the visual gain obtained after induction therapy, despite discontinuation of treatment during follow-up. Haemorrhages in the recurrences were associated with a worse final VA(AU)

[Long-term visual acuity in patients with age-related macular degeneration and persistence of subretinal fluid after treatment with ranibizumab]. / Agudeza visual a largo plazo en pacientes con degeneración macular asociada a la edad tratados con ranibizumab y persistencia de fluido subretiniano.

OBJECTIVE: To analyse the long-term visual acuity (VA) in patients with age-related macular degeneration (ARMD) treated with ranibizumab, and who had persistent subretinal fluid after the induction therapy and/or in the successive controls. MATERIALS AND METHODS: We reviewed the medical records, optical coherence tomography (OCT) and fluorescein angiograms of 216 patients treated with ranibizumab between January 2008 and April 2010, selecting those who had persistent subretinal fluid or recurrent fluid for at least one year of follow-up. RESULTS: A total of 36 eyes from 34 patients were included, with 19 eyes (52.7%) having persistent, and 17 (47.2%) recurrent subretinal fluid throughout the follow- up (mean 29.06±9.28 months). The average number of injections was 7.89±3.2. The central macular thickness (CMT) at the start of follow-up was 330±84µm, at 3 months 265.2±62µm, and 294.5±37µm at the end of the follow-up. The initial mean VA was 0.3±0.2, at 3 months 0.43±0.2 (P<.05) and at the final review, 0.41±0.22 (P<.05). Haemorrhages in recurrences were associated with a worse final VA (P=.004). At the end of follow-up, 18 eyes (50%) continued with ranibizumab treatment, 16 eyes (44%) were kept under observation, and 2 patients died. There were no differences between VA and CMT between the groups. CONCLUSIONS: The persistence or recurrence of macular subretinal fluid in patients treated with ranibizumab does not significantly reduce the visual gain obtained after induction therapy, despite discontinuation of treatment during follow-up. Haemorrhages in the recurrences were associated with a worse final VA.

[Ranibizumab as treatment for myopic choroidal neovascularization]. / Tratamiento de membranas neovasculares miópicas con Ranibizumab.

OBJECTIVE: To evaluate the efficacy of intravitreal Ranibizumab as treatment for choroidal neovascularisation due to pathological myopia. MATERIALS AND METHODS: A retrospective, non-comparative study of 18 eyes treated with intravitreal injections of Ranibizumab. Ten eyes had been treated previously with photodynamic therapy and eight received Ranibizumab as first therapy. After thorough ophthalmologic examination, fluorescein angiography (FAG) and optical coherence tomography (OCT), intraocular injection of Ranibizumab was performed. In subsequent monthly follow ups and taking into account visual acuity, presence or absence of metamorphopsia, biomicroscopy and OCT examination, further treatment was decided. RESULTS: Eighteen eyes from 16 patients were finally included. Patients were followed up for a minimum of 6 months. The mean age at initial treatment was 56.4 years. Mean refractive error was -13.3 diopters. Regarding FAG, all neovascular membranes were classical and sub or juxtafoveal localised. At the end of the sixth month after treatment fourteen eyes (77.7%) showed better visual acuity ranging from one or more lines on the Snellen chart, eleven eyes (61.1%) improved two lines or more, three eyes (16.6%) did not show any change and one eye (5.5%) worsened by one line. At 6 months the mean best-corrected visual acuity improved from 0.25 to 0.46 (p= 0.001). The mean central macular thickness decreased from 344.9 to 212.6 (p=0.015). CONCLUSIONS: Ranibizumab may be a good therapeutic option as treatment for choroidal neovascularisation due to pathological myopia; it improved visual acuity and anatomical features, even in non-responders to photodynamic therapy (Arch Soc Esp Oftalmol 2009; 84: 507-514).

Tratamiento de membranas neovasculares miópicas con ranibizumab / Ranibizumab as treatment for myopic choroidal neovascularization

Objetivo: Determinar la eficacia de Ranibizumab intravítreo, como tratamiento de la neovascularización coroidea asociada a miopía patológica. Material y métodos: Estudio retrospectivo, no comparativo de 18 ojos tratados con inyecciones intravítreas de Ranibizumab. Diez de los casos se habían tratado previamente con Terapia Fotodinámica, los 8 restantes recibieron Ranibizumab como primera terapia. Tras realizar angiografía fluoesceínica (AGF) y tomografía de coherencia óptica (OCT), se inyectaba ranibizumab, en los controles mensuales posteriores y teniendo en cuenta la agudeza visual (AV), presencia de metamorfopsias, biomicroscopia de polo posterior y características de la OCT se decidía el retratamiento. Resultados: Se analizaron 18 ojos de 16 pacientes, con un seguimiento mínimo de 6 meses. La edad media fue de 56,4 años y el equivalente esférico medio de -13,3 dioptrias. Todas las membranas neovasculares fueron angiográficamente clásicas y de localización sub o yuxtafoveal. La AV mejoró en 14 ojos (77,7%) al menos 1 línea y 11 ojos (61,1%) mejoraron 2 o más líneas a los 6 meses de la inyección, 3 ojos no mostraron cambio (16,6%) y sólo 1 empeoró 1 línea (5,5%). A los 6 meses la AV media mejoró de 0,25 a 0,46 (p = 0,001). La media del espesor macular en la OCT se redujo de 344,9 micras a 212,6 (p = 0,015). Conclusiones: Ranibizumab puede ser una buena opción terapéutica en el tratamiento de la neovascularización miópica, con mejoría visual y anatómica, incluso en pacientes no respondedores a Terapia Fotodinámica (AU)

Objective: To evaluate the efficacy of intravitreal Ranibizumab as treatment for choroidal neovascularisation due to pathological myopia. Materials and methods: A retrospective, non-comparative study of 18 eyes treated with intravitreal injections of Ranibizumab. Ten eyes had been treated previously with photodynamic therapy and eight received Ranibizumab as first therapy. After thorough ophthalmologic examination, fluorescein angiography (FAG) and optical coherence tomography (OCT), intraocular injection of Ranibizumab was performed. In subsequent monthly follow ups and taking into account visual acuity, presence or absence of metamorphopsia, biomicroscopy and OCT examination, further treatment was decided. Results: Eighteen eyes from 16 patients were finally included. Patients were followed up for a minimum of 6 months. The mean age at initial treatment was 56.4 years. Mean refractive error was -13.3 diopters. Regarding FAG, all neovascular membranes were classical and sub or juxtafoveal localised. At the end of the sixth month after treatment fourteen eyes (77.7%) showed better visual acuity ranging from one or more lines on the Snellen chart, eleven eyes (61.1%) improved two lines or more, three eyes (16.6%) did not show any change and one eye (5.5%) worsened by one line. At 6 months the mean best-corrected visual acuity improved from 0.25 to 0.46 (p= 0.001). The mean central macular thickness decreased from 344.9 to 212.6 (p=0.015). Conclusions: Ranibizumab may be a good therapeutic option as treatment for choroidal neovascularisation due to pathological myopia; it improved visual acuity and anatomical features, even in non-responders to photodynamic therapy (AU)

[Photodynamic therapy in retinal pigment epithelium detachment associated with long term central serous chorioretinopathy]. / Terapia fotodinámica en DEP avascular asociado a coriorretinopatía serosa central de larga evolución.

PURPOSE: To present a case of long term central serous corioretinopathy associated with chronic detachment of the retinal pigment epithelium (RPE) and the effect of photodynamic therapy on it. CASE CLINIC: We present the case of a 46-year old man with long term chronic central serous chorioretinopathy (18 mo.) with chronic detachment of RPE in his left eye who underwent PDT with Verteporfin (Visudyne). BCVA improved from 0.7 to 1 and metamorphopsia disappeared within one month of treatment. The patient remained asymptomatic for a follow-up period of 15 months. DISCUSSION: Choroidal hyperpermeability is found in central serous chorioretinopathy as a primary involvement factor. PDT with Verteporfin induces a transient reduction in choriocapilaris blood flow and can be used as treatment in cases of chronic central serous chorioretinopathy.

Terapia fotodinámica en Dep avascular asociado a coriorretinopatía serosa central de larga evolución / Photodynamic therapy in retinal pigment epitheliyn detachment associated with long term central serous chorioretinopathy

Objetivo: Describir un caso de coriorretinopatía serosa central asociada a un DEP crónico y el resultado de terapia fotodinámica sobre el mismo. Caso clínico: Se presenta el caso de un hombre de 46 años con coriorretinopatía serosa central crónica de larga evolución (18 meses) con desprendimiento crónico del EPR en su ojo izquierdo que se sometió a tratamiento con terapia fotodinámica con Verteporfin (Visudyne). La AV mejoró de 0,7 a 1, desapareciendo la metamorfopsia en un mes tras el tratamiento. El paciente permaneció asintomático durante un periodo de seguimiento de 15 meses. Discusión: La hiperpermeabilidad coroidea es un factor primario en el desarrollo de la coriorretinopatía serosa central. La terapia fotodinámica con Verteporfin induce una reducción transitoria en el flujo sanguíneo de la coriocapilar y se puede usar como tratamiento en casos de coriorretinopatía serosa central crónica

Purpose: To present a case of long term central serous corioretinopathy associated with chronic detachment of the retinal pigment epithelium (RPE) and the effect of photodynamic therapy on it. Case clinic: We present the case of a 46-year old man with long term chronic central serous chorioretinopathy (18 mo.) with chronic detachment of RPE in his left eye who underwent PDT with Verteporfin (Visudyne). BCVA improved from 0.7 to 1 and metamorphopsia disappeared within one month of treatment. The patient remained asymptomatic for a follow-up period of 15 months. Discussion: Choroidal hyperpermeability is found in central serous chorioretinopathy as a primary involvement factor. PDT with Verteporfin induces a transient reduction in choriocapilaris blood flow and can be used as treatment in cases of chronic central serous chorioretinopathy (Arch Soc Esp Oftalmol 2008; 83: 545-548)

[A case of punctate inner choroidopathy: differential diagnosis]. / A propósito de un caso de coroidopatía puntata interna: diagnóstico diferencial.

CASE REPORT: We present the case of a 27-year old woman suffering from a chorioretinal inflammatory disease that was diagnosed as punctate inner choroidopathy (PIC) after a complete ophthalmic evaluation. DISCUSSION: PIC must be taken into consideration when evaluating a patient with a white dot syndrome.

A propósito de un caso de coroidopatía puntata interna: diagnóstico diferencial / A case of punctate inner choroidopathy: differential diagnosis

Caso clínico: Presentamos el caso de una joven de 27 años con una enfermedad inflamatoria coriorretiniana que tras su estudio es diagnosticada de una coroidopatía punctata interna (PIC).Discusión: La PIC debe diferenciarse de otras patologías similares a veces de diagnóstico diferencial difícil, que son denominadas bajo el sobrenombre de 'síndromes de puntos blancos' (AU)

No disponible

Efecto del pranoprofeno tópico en la lipooxigenación del ácido araquidónico en la uveítis inducida por endotoxina / Effect of topical pranoprofen on the lipoxygenase metabolism of the arachidonic and in endotoxin-induced uveitis

Objetivo: Estudiamos el efecto del pranoprofeno sobre la lipooxigenación del ácido araquidónico en conejos albinos. Métodos: La uveítis se produjo mediante la inyección intravítrea de 10 nanogramos de lipopolisacárido A de Salmonella typhimurium disueltos en 5 µl suero salino apirético. Se utilizaron 5 grupos de 12 animales a los que se les inyectó en el vítreo del ojo derecho: 5 µl de suero al grupo control y 5 µl de solución de endotoxina a los cuatro grupos restantes. Además a los grupos III, IV y V se les administró pranoprofeno tópico 2 horas antes de la inyección intravítrea, inmediatamente después y cada 6, 4 y 2 horas respectivamente. A las 24 horas se determinó en humor acuoso la concentración de células inflamatorias y de leucotrieno B4.Resultados: En los tres grupos de tratamiento con pranoprofeno se observó una reducción estadísticamente significativa de la concentración de células inflamatorias respecto al grupo de endotoxina (G-II); no se observaron diferencias significativas en cuanto a la determinación del leucotrieno B4 con relación al grupo de endotoxina. Conclusión: Concluimos que el pranoprofeno tópico no potencia la lipooxigenación del ácido araquidónico (AU)

Capacidad antiinflamatoria del Ketorolaco tópico en un modelo experimental de inflamación ocular / Antiinflammatory capacity of topical Ketorolac in experimental model of ocular inflammation

Objetivo: Estudiar la capacidad antiinflamatoria del Ketorolaco-Trometamina administrado por vía tópica sobre un modelo de uveítis inducida por endotoxina en conejos albinos. Métodos: Desarrollamos la uveítis experimental en el ojo derecho mediante la administración intravítrea de 10 ng de lipopolisacárido (LPS) A de Salmonella typhimurium disueltos en 5 µl de suero salino. Hemos utilizado 60 animales (5 grupos de 12); al grupo control (G-I) se le inyectó en vítreo 5 µl de suero salino; al grupo de endotoxina (ET) (G-II) se le inyectó 5 µl de solución de ET; a los grupos III, IV y V se les inyectó la ET y se les aplicó Ketorolaco-Trometamina por vía tópica cada 6, 4 y 2 horas respectivamente. Se sacrificaron los animales a las 24 horas determinándose la clínica (hiperemia ciliar, del iris y Tyndall en cámara anterior) y la concentración de células inflamatorias y proteínas en humor acuoso. Resultados: Observamos cómo, en todos los grupos tratados con Ketorolaco-Trometamina, se reducen de forma significativa (p<0,05) todos los parámetros estudiados respecto al grupo de endotoxina (G-II).Conclusiones: El Ketorolaco-Trometamina aplicado de manera tópica reduce eficazmente la respuesta inflamatoria en un modelo de uveítis inducida por endotoxina (AU)

Capsulotomía Nd-YAG y antibióticos intravítreos como tratamiento de la endoftalmitis crónica / Postoperatoria chronice postoperative endophthalmitis

Objetivo: Estudiar la eficacia de la combinación capsulotomía YAG aspiración vítrea e inyección intravítrea de antibióticos en el tratamiento de las endoftalmitis crónicas postoperatorias. Métodos: Seis pacientes que tras una técnica quirúrgica oftalmológica con implantación de lente intraocular (LIO) padecen un cuadro inflamatorio crónico intraocular rebelde a tratamiento médico y/o quirúrgico. Primero, realizamos una capsulotomía YAG, seguidamente procedemos a la aspiración de humor vítreo, vía pars plana, e inyección de antibióticos. Resultados: En cuatro casos (un 66 por ciento) conseguimos aislar el germen responsable, tres estafilococos coagulasa negativo y un Corynebacterium spp. En todos los casos controlamos el cuadro inflamatorio y obtuvimos una mejoría notable en la agudeza visual (AV), con ausencia de recidivas (en tres casos el seguimiento es limitado por la muerte de dos pacientes y en el otro por acaecer en fechas próximas).Conclusiones: Nosotros, pensamos que la capsulotomía YAG previa facilita la destrucción del santuario infeccioso (el saco capsular), por una parte, y el aislamiento y erradicación del agente infeccioso, por otra. Esta sucesión terapéutica es una alternativa eficaz, ambulatoria y de fácil práctica para el Oftalmólogo en el tratamiento de las endoftalmitis crónicas postoperatorias (AU)

No disponible

Coroidopatía central serosa. Estudio a largo plazo / Central serous choroidopathy. Long term outcome

Objetivo: Determinar las características epidemiológicas, clínicas y la evolución a largo plazo de la coroidopatía central serosa (CCS) en nuestro medio. Métodos: Se han revisado retrospectivamente las historias clínicas y AGF de 113 pacientes diagnosticados de CCS en nuestro Servicio, con un seguimiento mínimo de 1 año. Resultados: De los 113 pacientes, 90 fueron hombres y 23 mujeres, 13 de ellos bilaterales. En el 85,7 por ciento de los ojos (Grupo I) la evolución fue buena, con resolución de los síntomas en meses y agudeza visual (AV) media al final del estudio de 79,3/100, mientras que el 14,3 por ciento de los ojos evolucionó de forma crónica (Grupo II), con afectación difusa del EPR y AV media final de 47,2/100. La edad media en el Grupo II fue de 42,5 años, significativamente mayor que en el Grupo I (37,6 años) y el porcentaje de hombres del Grupo II (93,3 por ciento) significativamente superior al del grupo I (77,6 por ciento). El porcentaje de bilateralidad fue del 6 por ciento en el Grupo I, frente al 46,6 por ciento del Grupo II. Conclusiones: La forma crónica de CSC afecta a menos del 15 por ciento de los pacientes. La edad media de estos pacientes es superior a la de la forma típica, la gran mayoría son varones, afecta a los 2 ojos en casi el 50 por ciento de los casos, con deterioro importante de visión en el 50 por ciento de los ojos (AU)

No disponible

[Central serous choroidopathy. Long term study]. / Coroidopatía central serosa. Estudio a largo plazo.

PURPOSE: To investigate the demographic characteristics, clinical findings and long-term outcome of central serous chorioretinopathy (CSC). METHODS: This study examined retrospectively the clinical stories and fluorescein angiographies of 113 patients with CSC and a minimum follow-up of 12 months. RESULTS: A total of 113 patients was examined; 90 were men and 23 women. Bilateral involvement was found in 13 cases. In 85.7% of the eyes (Group I) resolution was completed in months and mean final visual acuity (VA) was 79.3/100, while 14.3% of the eyes (Group II) showed a chronic evolution, with diffuse retinal pigment epithelipathy and mean final VA of 47.2/100. The mean age of the patients in Group II was significantly higher; male:female ratio was also higher in this Group. Bilateral involvement occurred in 6% of patients from Group I and in 46.6% in Group II. CONCLUSIONS: Chronic CSC affected less than 15% of the patients. Mean age in this group of patients was higher than in patients with a classic CSC, most of the cases were men, bilateral involvement was present in nearly 50% of the cases and 50% of them suffered a significant visual permanent impairment.

[Nd-YAG capsulotomy and intravitreal antibiotics as treatment of chronic endophthalmitis]. / Capsulotomía Nd-YAG y antibióticos intravítreos como tratamiento de la endoftalmitis crónica.

PURPOSE: To study the effectiveness of Yag capsulotomy, therapeutic vitreal aspiration and intravitreal injection of antibiotics combination on the treatment of chronic postoperative endophthalmitis. METHODS: Six patients with symptoms of refractory postoperative endophthalmitis after extracapsular cataract extraction, with an intraocular lens were treated following a protocol that included: YAG capsulotomy, vitreal aspiration and intravitreal injection of antibiotics. RESULTS: In four cases -66%- the micro-organism was isolated -three cases of coagulase- negative staphylococci and one case Corynebacterium spp. In all the cases the inflammatory process decreased, and a noticeable improvement of visual acuity was achieved. No recurrent cases were observed (two patients died before the end of the study). CONCLUSIONS: As way of conclusion we can state that the initial capsulotomy allows the destruction of the infection reservoir in order to eradicate the agent. This endophthalmitis therapeutic alternative is effective, easy and reliable for the ophthalmologist.

[Antiinflammatory capacity of topical ketorolac in experimental model of ocular inflammation]. / Capacidad antiinflamatoria del Ketorolaco tópico en un modelo experimental de inflamación ocular.

PURPOSE: We studied the antiinflammatory effect of topical Ketorolac-Tromethamine on a model of endotoxin-induced uveitis in albino rabbits. METHODS: Endotoxin-induced uveitis was produced by intravitreal injection in the right eye of 10 ng lipopolysaccharide (LPS) A Salmonella typhimurium endotoxin in 5 microl saline solution. We have used 60 animals (5 groups of 12 animals each). Control group (G-I) was injected with saline (5 microl); endotoxin group (G-II) was injected with 10 ng of endotoxin; groups III, IV and V were injected with the same amount of endotoxin and treated with topical ketorolac-tromethamine every 6, 4 and 2 hours respectively. The animals were sacrificed 24 hours after endotoxin administration. We determined the ocular clinical signs and inflammatory cells and protein concentration in the aqueous humor. RESULTS: In all the groups treated with Ketorolac-Tromethamine we observed a significant reduction (p<0.05) in all parameters studied when compared with those of the endotoxin group (G-II). CONCLUSION: Topical Ketorolac-Tromethamine has demonstrated a significant reduction of endotoxin-induced-uveitis inflammation.

[Effect of topical pranoprofen on the lipoxygenase metabolism of the arachidonic and in endotoxin-induced uveitis]. / Efecto del pranoprofeno tópico en la lipooxigenación del ácido araquidónico en la uveítis inducida por endotoxina.

PURPOSE: To study the antiinflammatory effect of topical pranoprofen on the lipoxygenase metabolism of the arachidonic acid in albino rabbits. METHODS: Endotoxin-induced uveitis (EIU) was produced in albino rabbits by intravitreal injection in the right eye with 10 microg of Salmonella typhymurium lipopolysacharide A in 5 microl saline solution. We have used 5 groups of 12 animals each. Control group (G-I) was injected with 5 microl of saline solution and 5 microl of ET solution were injected in the remaining groups. Groups III, IV and V were treated with topical pranoprofen 2 hours before intravitreal injection, immediately after and every 6, 4 and 2 hours respectively. The animals were sacrificed 24 hours after the ET administration. Cellular and B4 leukotrien concentration in the aqueous humour was determined. RESULTS: The groups treated with pranoprofen showed a significant decrease in the cellular concentration in relation to the group of endotoxin (G-II). We did not observe any difference in the B4 leukotriene concentration between ET group and topical pranoprofen groups. CONCLUSION: Topical pranoprofen has not increased the lipoxygenase metabolism of the arachidonic acid.